Skip to main content

Advertisement

Table 3 Details of included combination therapy RCTs*

From: Network meta-analysis combining individual patient and aggregate data from a mixture of study designs with an application to pulmonary arterial hypertension

Reference Barst 2011 (PHIRST-1) Simonneau 2008 (PACES) McLaughlin 2006 (STEP) Humbert 2004 (BREATHE-2)
Baseline therapy ERA Pr (iv epo) ERA None
Add-on therapy PDE5i Placebo PDE5i Placebo Pr (inh ilp) Placebo ERA ERA+ Pr (iv epo)
Treatment dose 40 mg tadalafil once daily 3x20mg sildenafil daily, increased to 40 and 80 at 4 week intervals 5 μg inhaled iloprost 62.5 mg bosentan twice daily, increased to 125 mg twice daily after 4 weeks. Intravenous epoprostenol started at 2 ng/kg/min and increased up to 14 ± 2 ng/kg/min after 16 weeks.
Patients at end of trial 42 45 133 123 34 33 19 10
Duration 16 weeks 16 weeks 12 weeks 16 weeks
Change 6MWD 40.2 (8.5) 18.8 (9.2) 29.8 (5.3) 1 (5.3) 30 (10.3) 4 (10.6) 72 (11.47) 46 (19.61)
Baseline 6MWD 360.9 (11.6) 348.5 (12.7) 348.9 (6.2) 341 (6.7) 331 (73) 340 (64) 323.04§ 323.62§
Age 50 51.7 47.8 47.5 49 51 45 47
Sex (% male) 0.21 0.22 0.18 0.23 0.21 0.21 0.23 0.45
STATUS 2.5 2.7 2.8 2.8 3.0 3.0 3.23 3.27
PVR 863.3 863.3 856.8 754.9 815 783 1511 1426
  1. *E are endothelin receptor antagonists, P5 are phosphodiesterase 5 inhibitors, Pr are prostacyclin analogues. iv ep is intravenous epoprostenol, inh ilp is inhaled iloprost.
  2. §Imputed based on linear model for baseline 6MWD with covariates for Age, Sex, mean STATUS, and mean right arterial pressure.